Today: 9 April 2026
Subscribe
Browse Category

TSXV:SGML 17 November 2025

Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium shares surged over 30% in premarket U.S. trading Monday, hitting as high as $8.20 on volume exceeding 12 million shares. The rally follows strong Q3 2025 results and a bullish lithium demand forecast from China’s Ganfeng Lithium. Sigma closed Friday at $6.06, up 2.7% on heavy volume. Lithium futures in Guangzhou jumped 9% after Ganfeng projected 30% demand growth in 2026.
17 November 2025
···

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:15 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop